ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

N/AUnknownNCT05032001

Metabolic Research Unit30 enrolled

Overview

Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Abdominal Obesity Type 2 Diabetes

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients +18 years * Patients with visceral fat quantification by BIA at baseline and week twelve * Patients with body mass index \>25 * Patients can swallow tablets Exclusion Criteria: * Patients treated with other oral antidiabetic agents or insulin * Glomerular filtration rate less than 30 mL/min * Transaminemia greater than 2 times the upper reference value * Pregnancy * Malnutrition

Outcomes

Primary Outcomes

Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve

Bioimpedance is a confident method to measured visceral fat

Time frame: Baseline and week twelve